Pharmacogenetics and treatment-resistant schizophrenia

Adriana Foster, Peter F. Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

Original languageEnglish (US)
Title of host publicationTreatment-Refractory Schizophrenia: A Clinical Conundrum
PublisherSpringer Berlin Heidelberg
Pages179-194
Number of pages16
ISBN (Print)9783642452574, 9783642452567
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pharmacogenetics
Schizophrenia
Genetic Polymorphisms
Therapeutics
Neurotransmitter Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Foster, A., & Buckley, P. F. (2014). Pharmacogenetics and treatment-resistant schizophrenia. In Treatment-Refractory Schizophrenia: A Clinical Conundrum (pp. 179-194). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-45257-4_12

Pharmacogenetics and treatment-resistant schizophrenia. / Foster, Adriana; Buckley, Peter F.

Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. p. 179-194.

Research output: Chapter in Book/Report/Conference proceedingChapter

Foster, A & Buckley, PF 2014, Pharmacogenetics and treatment-resistant schizophrenia. in Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, pp. 179-194. https://doi.org/10.1007/978-3-642-45257-4_12
Foster A, Buckley PF. Pharmacogenetics and treatment-resistant schizophrenia. In Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg. 2014. p. 179-194 https://doi.org/10.1007/978-3-642-45257-4_12
Foster, Adriana ; Buckley, Peter F. / Pharmacogenetics and treatment-resistant schizophrenia. Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. pp. 179-194
@inbook{1f57e050a30d47a89f1d3a02040520dd,
title = "Pharmacogenetics and treatment-resistant schizophrenia",
abstract = "It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.",
author = "Adriana Foster and Buckley, {Peter F.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-45257-4_12",
language = "English (US)",
isbn = "9783642452574",
pages = "179--194",
booktitle = "Treatment-Refractory Schizophrenia: A Clinical Conundrum",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Pharmacogenetics and treatment-resistant schizophrenia

AU - Foster, Adriana

AU - Buckley, Peter F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

AB - It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84956772746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956772746&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45257-4_12

DO - 10.1007/978-3-642-45257-4_12

M3 - Chapter

AN - SCOPUS:84956772746

SN - 9783642452574

SN - 9783642452567

SP - 179

EP - 194

BT - Treatment-Refractory Schizophrenia: A Clinical Conundrum

PB - Springer Berlin Heidelberg

ER -